173 related articles for article (PubMed ID: 24138841)
21. Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel.
Kaufmann M; Pusztai L;
Cancer; 2011 Apr; 117(8):1575-82. PubMed ID: 21472705
[TBL] [Abstract][Full Text] [Related]
22. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX.
Kaklamani V
Expert Rev Mol Diagn; 2006 Nov; 6(6):803-9. PubMed ID: 17140367
[TBL] [Abstract][Full Text] [Related]
23. Gene expression profiling in breast cancer.
Morris SR; Carey LA
Curr Opin Oncol; 2007 Nov; 19(6):547-51. PubMed ID: 17906450
[TBL] [Abstract][Full Text] [Related]
24. Application Of Multigene Panel Detection In Breast Cancer.
Zhao Y; Xiong D; Yang B; Xia S; Zhang X
J Pak Med Assoc; 2023 Sep; 73(9):1862-1868. PubMed ID: 37817699
[TBL] [Abstract][Full Text] [Related]
25. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
Harbeck N; Thomssen C
Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518
[TBL] [Abstract][Full Text] [Related]
26. Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks.
Roukos DH; Ziogas DE; Katsios C
Expert Rev Anticancer Ther; 2010 Aug; 10(8):1187-95. PubMed ID: 20735306
[TBL] [Abstract][Full Text] [Related]
27. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
28. Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer.
Markopoulos C
Expert Rev Anticancer Ther; 2013 Feb; 13(2):179-94. PubMed ID: 23406559
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
Yang M; Rajan S; Issa AM
Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
[TBL] [Abstract][Full Text] [Related]
30. Genomic Signatures in Luminal Breast Cancer.
Puppe J; Seifert T; Eichler C; Pilch H; Mallmann P; Malter W
Breast Care (Basel); 2020 Aug; 15(4):355-365. PubMed ID: 32982645
[TBL] [Abstract][Full Text] [Related]
31. Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
Jacobs VR; Kates RE; Kantelhardt E; Vetter M; Wuerstlein R; Fischer T; Schmitt M; Jaenicke F; Untch M; Thomssen C; Harbeck N
Breast Cancer Res Treat; 2013 Apr; 138(3):839-50. PubMed ID: 23568480
[TBL] [Abstract][Full Text] [Related]
32. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
National Institutes of Health Consensus Development Panel
J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
[TBL] [Abstract][Full Text] [Related]
33. Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?
Glück S; Yip AY; Ng EL
Expert Opin Ther Targets; 2012 Mar; 16 Suppl 1():S17-22. PubMed ID: 22316427
[TBL] [Abstract][Full Text] [Related]
34. [Gene expression based multigene prognostic and predictive tests in breast cancer].
Pénzváltó Z; Mihály Z; Gyorffy B
Magy Onkol; 2009 Dec; 53(4):351-9. PubMed ID: 20071307
[TBL] [Abstract][Full Text] [Related]
35. Clinical roundtable monograph: a multidisciplinary approach to the use of oncotype DX in clinical practice.
Gradishar WJ; Hansen NM; Susnik B
Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-7. PubMed ID: 19536946
[TBL] [Abstract][Full Text] [Related]
36. [Considerations in rational use of tumor markers in breast carcinoma].
Crombach G
Praxis (Bern 1994); 1998 Apr; 87(17):589-94. PubMed ID: 9623326
[TBL] [Abstract][Full Text] [Related]
37. Personalized treatment of early-stage breast cancer: present concepts and future directions.
Harbeck N; Salem M; Nitz U; Gluz O; Liedtke C
Cancer Treat Rev; 2010 Dec; 36(8):584-94. PubMed ID: 20554119
[TBL] [Abstract][Full Text] [Related]
38. Prediction of benefit from adjuvant treatment in patients with breast cancer.
Eng-Wong J; Isaacs C
Clin Breast Cancer; 2010; 10 Suppl 1():E32-7. PubMed ID: 20587405
[TBL] [Abstract][Full Text] [Related]
39. Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.
Di Leo A; Cardoso F; Durbecq V; Giuliani R; Mano M; Atalay G; Larsimont D; Sotiriou C; Biganzoli L; Piccart MJ
Int J Clin Oncol; 2002 Aug; 7(4):245-53. PubMed ID: 12202978
[TBL] [Abstract][Full Text] [Related]
40. A new look at node-negative breast cancer.
Harbeck N; Thomssen C
Oncologist; 2011; 16 Suppl 1():51-60. PubMed ID: 21278441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
